Professional Media briefs: May 2014

Ivan Oransky
Ivan Oransky

BMJ and the Lupus Foundation of America have published the first articles for Lupus Science & Medicine, which the partners said is the first lupus-specific open-access journal. Lupus Foundation CEO and President Sandra Raymond said in a statement that the foundation's publishing efforts have been scattered across non-lupus publications and that this journal “provides a much needed, centralized home for… lupus research findings.”

MedPage Today's Ivan Oransky's Retraction Watch has launched a subscriber service. Oransky (pictured) and partner Adam Marcus announced the service in a March post, alerting readers that subscriptions to the four-year-old blog would go toward such things as paying writers and creating a database. Funds will be handled by a third party, so as to protect the site's independence.

John Wiley & Sons has updated its 2006 Best Practice Guidelines on Publishing Ethics: A Publisher's Perspective. The goal remains to be a touchstone for advice on what the company calls “the major ethical principles of academic publishing.” The new edition includes guidance about whistle-blowers, clinical trial registration and other subjects.

You must be a registered member of MMM to post a comment.

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.